The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.
A one-on-one conversation with Zachary Brennan, Senior Editor at Endpoints, and an industry leader discussing issues at the forefront of rare disease drug development.
Senior Editor
Endpoints News
What can biopharma companies expect from the recent court rulings around the abortion pill mifepristone and FDA's reaction?
Professor of Law
Drexel University Kline School of Law
Senior Lecturer Co-Director, Center for Law and the Public’s Health
Johns Hopkins Bloomberg School of Public Health
Physician-Anthropologist of Public Health and Law
Northwestern University
Senior Editor
Endpoints News